Publication | Open Access
High seroprevalence but short-lived immune response to SARS-CoV-2 infection in Paris
13
Citations
28
References
2020
Year
Unknown Venue
Virus EpidemiologyViral DiagnosticsImmunodeficienciesViral ImmunityImmunologyCovid-19 EpidemiologyCovid-19Pseudo-neutralization ActivityViral PersistenceSerologic TestingPublic HealthLong CovidCovid-19 PandemicVirologySystemic IggsEpidemiologySerological ResponseVaccinationHigh SeroprevalenceEmerging Infectious DiseasesSars-cov-2 InfectionMedicineShort-lived Immune Response
ABSTRACT Although the COVID-19 pandemic peaked in March/April 2020 in France, the prevalence of infection is barely known. Herein, we assessed using high-throughput methods the serological response against the SARS-CoV-2 virus of 1847 participants working in one institution in Paris. In May-July 2020, 11% (95% CI: 9.7-12.6) of serums were positive for IgG against the SARS-CoV-2 N and S proteins and 9.5% (CI:8.2-11.0) were pseudo-neutralizer. The prevalence of immunization was 11.6% (CI:10.2-13.2) considering positivity in at least one assays. In 5% (CI:3.9-7.1) of RT-qPCR positive individuals, no systemic IgGs were detected. Among immune individuals, 21% had been asymptomatic. Anosmia and ageusia occurred in 52% of the IgG-positive individuals and in 3% of the negative ones. In contrast, 30% of the anosmia-ageusia cases were seronegative suggesting that the true prevalence of infection may reach 16.6%. In sera obtained 4-8 weeks after the first sampling anti-N and anti-S IgG titers and pseudo-neutralization activity declined by 31%, 17% and 53%, respectively with half-life of 35, 87 and 28 days, respectively. The population studied is representative of active workers in Paris. The short lifespan of the serological systemic responses suggests an underestimation the true prevalence of infection.
| Year | Citations | |
|---|---|---|
Page 1
Page 1